BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23136886)

  • 1. Direct AMP-activated protein kinase activators: a review of evidence from the patent literature.
    Giordanetto F; Karis D
    Expert Opin Ther Pat; 2012 Dec; 22(12):1467-77. PubMed ID: 23136886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMP-activated protein kinase modulators: a patent review (2006 - 2010).
    Yun H; Ha J
    Expert Opin Ther Pat; 2011 Jul; 21(7):983-1005. PubMed ID: 21548715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the 5'-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer.
    Popovics P; Frigo DE; Schally AV; Rick FG
    Expert Opin Ther Targets; 2015 May; 19(5):617-32. PubMed ID: 25600663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening methods for AMP-activated protein kinase modulators: a patent review.
    Kim J; Shin J; Ha J
    Expert Opin Ther Pat; 2015 Mar; 25(3):261-77. PubMed ID: 25535089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Targeting of AMP-Activated Protein Kinase and Opportunities for Computer-Aided Drug Design.
    Miglianico M; Nicolaes GA; Neumann D
    J Med Chem; 2016 Apr; 59(7):2879-93. PubMed ID: 26510622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential upstream regulators and downstream targets of AMP-activated kinase signaling during oocyte maturation in a marine worm.
    Stricker SA
    Reproduction; 2011 Jul; 142(1):29-39. PubMed ID: 21474604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-MET kinase inhibitors: a patent review (2011 - 2013).
    Zhu K; Kong X; Zhao D; Liang Z; Luo C
    Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promise and challenges for direct small molecule AMPK activators.
    Olivier S; Foretz M; Viollet B
    Biochem Pharmacol; 2018 Jul; 153():147-158. PubMed ID: 29408352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p21-Activated kinase inhibitors: a patent review.
    Crawford JJ; Hoeflich KP; Rudolph J
    Expert Opin Ther Pat; 2012 Mar; 22(3):293-310. PubMed ID: 22404134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer.
    Cao W; Li J; Hao Q; Vadgama JV; Wu Y
    Breast Cancer Res; 2019 Feb; 21(1):29. PubMed ID: 30791936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).
    Gehringer M; Muth F; Koch P; Laufer SA
    Expert Opin Ther Pat; 2015; 25(8):849-72. PubMed ID: 25991433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMPK activators--potential therapeutics for metabolic and other diseases.
    Zhou G; Sebhat IK; Zhang BB
    Acta Physiol (Oxf); 2009 May; 196(1):175-90. PubMed ID: 19245659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in the identification of adenosine monophosphate-activated protein kinase (AMPK) activators.
    Cameron KO; Kurumbail RG
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5139-5148. PubMed ID: 27727125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation.
    Salt IP; Palmer TM
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1155-67. PubMed ID: 22694351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
    Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
    Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of WO-2013040863, WO-2013041042 and WO-2013043962. Selective JAK1 inhibitors based on a 3-aminopyrazole-4-carboxamide scaffold.
    Norman P
    Expert Opin Ther Pat; 2014 Feb; 24(2):231-7. PubMed ID: 24261748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation and signaling by the AMP-activated protein kinase in endothelial cells.
    Fisslthaler B; Fleming I
    Circ Res; 2009 Jul; 105(2):114-27. PubMed ID: 19608989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rho kinase inhibitors: a patent review (2012 - 2013).
    Feng Y; LoGrasso PV
    Expert Opin Ther Pat; 2014 Mar; 24(3):295-307. PubMed ID: 24283930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.